Dina L. Masi - 21 May 2025 Form 4 Insider Report for INTEGRATED BIOPHARMA INC (INBP)

Reporting relationship: Chief Financial Officer
Issuer ticker: INBP
Reported as of: 21 May 2025
Net transaction value: +$12,150
SEC form: 4
Accepted by SEC: 22 May 2025, 17:41:44 UTC
Prior SEC filing: 05 Dec 2024
Next SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Dina L Masi

Key filing fact

Dina L. Masi filed Form 4 for INTEGRATED BIOPHARMA INC (INBP) on 22 May 2025.

Key facts

This page summarizes Dina L. Masi's Form 4 filing for INTEGRATED BIOPHARMA INC (INBP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 May 2025, 17:41.

Change

Previous filing in this sequence was filed on 05 Dec 2024.
Current net transaction value: +$12,150.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001345281 Primary reporting owner

Masi Dina

Relationship: Chief Financial Officer
Address: 14 LEXINGTON WAY, LONG VALLEY
Signature: /s/ Dina L Masi
Signature date: 22 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INBP transaction

Common Stock

Award

Transaction value: $12,150
Shares: +135,000
Change %: +64%
Price: $0.0900
Shares after: 347,200
Date: 21 May 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBP transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -135,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 21 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 135,000
Exercise price: $0.0900
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

135,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015.

Footnote F2

72,500 of the options became exercisable on June 2, 2015 and the remaining 62,500 became exercisable in three equal annual installments beginning on June 2, 2016.